The 36-month beta value for INSM is also noteworthy at 0.79. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 6 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for INSM is 177.97M, and at present, short sellers hold a 9.25% of that float. The average trading volume of INSM on June 04, 2025 was 2.30M shares.
INSM) stock’s latest price update
The stock price of Insmed Inc (NASDAQ: INSM) has surged by 1.95 when compared to previous closing price of 71.68, but the company has seen a 7.44% gain in its stock price over the last five trading sessions. prnewswire.com reported 2025-05-28 that BRIDGEWATER, N.J., May 28, 2025 /PRNewswire/ — Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the 2025 Goldman Sachs Annual Global Healthcare Conference in Miami on Wednesday, June 11, 2025, at 9:20 a.m.
INSM’s Market Performance
Insmed Inc (INSM) has experienced a 7.44% rise in stock performance for the past week, with a 1.08% rise in the past month, and a -5.35% drop in the past quarter. The volatility ratio for the week is 1.45%, and the volatility levels for the past 30 days are at 2.81% for INSM. The simple moving average for the past 20 days is 7.83% for INSM’s stock, with a -0.06% simple moving average for the past 200 days.
Analysts’ Opinion of INSM
Many brokerage firms have already submitted their reports for INSM stocks, with Jefferies repeating the rating for INSM by listing it as a “Buy.” The predicted price for INSM in the upcoming period, according to Jefferies is $105 based on the research report published on May 13, 2025 of the current year 2025.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see INSM reach a price target of $100. The rating they have provided for INSM stocks is “Outperform” according to the report published on February 25th, 2025.
Truist gave a rating of “Buy” to INSM, setting the target price at $48 in the report published on April 23rd of the previous year.
INSM Trading at 4.11% from the 50-Day Moving Average
After a stumble in the market that brought INSM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.93% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INSM starting from Bonstein Sara, who proposed sale 1,579 shares at the price of $71.50 back on Jun 03 ’25. After this action, Bonstein Sara now owns shares of Insmed Inc, valued at $112,898 using the latest closing price.
Flammer Martina M.D., the Officer of Insmed Inc, proposed sale 1,686 shares at $71.50 during a trade that took place back on Jun 03 ’25, which means that Flammer Martina M.D. is holding shares at $120,549 based on the most recent closing price.
Stock Fundamentals for INSM
Current profitability levels for the company are sitting at:
- -2.3 for the present operating margin
- 0.76 for the gross margin
The net margin for Insmed Inc stands at -2.66. The total capital return value is set at -0.56. Equity return is now at value -890.75, with -68.42 for asset returns.
Based on Insmed Inc (INSM), the company’s capital structure generated 0.92 points at debt to capital in total, while cash flow to debt ratio is standing at -0.67. The debt to equity ratio resting at 11.53. The interest coverage ratio of the stock is -10.72.
Currently, EBITDA for the company is -814.14 million with net debt to EBITDA at -0.8. When we switch over and look at the enterprise to sales, we see a ratio of 36.88. The receivables turnover for the company is 7.98for trailing twelve months and the total asset turnover is 0.21. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.86.
Conclusion
In summary, Insmed Inc (INSM) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
